Jessica J. Kandel to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications Jessica J. Kandel has written about Xenograft Model Antitumor Assays.
Connection Strength
0.317
-
Monitoring early tumor response to drug therapy with diffuse optical tomography. J Biomed Opt. 2012 Jan; 17(1):016014.
Score: 0.093
-
Effects of potent VEGF blockade on experimental Wilms tumor and its persisting vasculature. Int J Oncol. 2004 Sep; 25(3):549-53.
Score: 0.056
-
Human epidermal growth factor receptor signaling contributes to tumor growth via angiogenesis in her2/neu-expressing experimental Wilms' tumor. J Pediatr Surg. 2003 Nov; 38(11):1569-73.
Score: 0.053
-
Perfusion-guided sonopermeation of neuroblastoma: a novel strategy for monitoring and predicting liposomal doxorubicin uptake in vivo. Theranostics. 2020; 10(18):8143-8161.
Score: 0.042
-
Notch suppresses angiogenesis and progression of hepatic metastases. Cancer Res. 2015 Apr 15; 75(8):1592-602.
Score: 0.029
-
Sustained VEGF blockade results in microenvironmental sequestration of VEGF by tumors and persistent VEGF receptor-2 activation. Mol Cancer Res. 2008 Jan; 6(1):1-9.
Score: 0.018
-
Inhibition of cyclooxygenase-2 disrupts tumor vascular mural cell recruitment and survival signaling. Cancer Res. 2006 Apr 15; 66(8):4378-84.
Score: 0.016
-
Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis. J Pediatr Surg. 2003 Mar; 38(3):308-14; discussion 308-14.
Score: 0.013